Literature DB >> 35570231

Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model.

Jie-Ming Jian1, Dong-Yu Fan1,2, Ding-Yuan Tian1, Yuan Cheng1, Pu-Yang Sun1, Cheng-Rong Tan1, Gui-Hua Zeng1, Chen-Yang He1, Ye-Ran Wang1, Jie Zhu1, Xiu-Qing Yao3, Yan-Jiang Wang4,5,6, Yu-Hui Liu7.   

Abstract

Increased neuronal apoptosis is an important pathological feature of Alzheimer's disease (AD). The Bcl-2-interacting mediator of cell death (Bim) mediates amyloid-beta (Aβ)-induced neuronal apoptosis. Naturally-occurring antibodies against Bim (NAbs-Bim) exist in human blood, with their levels and functions unknown in AD. In this study, we found that circulating NAbs-Bim were decreased in AD patients. Plasma levels of NAbs-Bim were negatively associated with brain amyloid burden and positively associated with cognitive functions. Furthermore, NAbs-Bim purified from intravenous immunoglobulin rescued the behavioral deficits and ameliorated Aβ deposition, tau hyperphosphorylation, microgliosis, and neuronal apoptosis in APP/PS1 mice. In vitro investigations demonstrated that NAbs-Bim were neuroprotective against AD through neutralizing Bim-directed neuronal apoptosis and the amyloidogenic processing of amyloid precursor protein. These findings indicate that the decrease of NAbs-Bim might contribute to the pathogenesis of AD and immunotherapies targeting Bim hold promise for the treatment of AD.
© 2022. Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-beta; Bim; Naturally-occurring antibodies; Neuronal apoptosis

Mesh:

Substances:

Year:  2022        PMID: 35570231      PMCID: PMC9468199          DOI: 10.1007/s12264-022-00869-y

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.271


  39 in total

1.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

Review 2.  The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  Acta Neuropathol       Date:  2013-09-20       Impact factor: 17.088

3.  Early Intervention in Alzheimer's Disease: How Early is Early Enough?

Authors:  Dong-Yu Fan; Yan-Jiang Wang
Journal:  Neurosci Bull       Date:  2019-09-07       Impact factor: 5.203

4.  Bim contributes to the progression of Huntington's disease-associated phenotypes.

Authors:  Sheridan L Roberts; Tracey Evans; Yi Yang; Yuhua Fu; Robert W Button; Rebecca J Sipthorpe; Katrina Cowan; Evelina Valionyte; Oleg Anichtchik; Huiliang Li; Boxun Lu; Shouqing Luo
Journal:  Hum Mol Genet       Date:  2020-01-15       Impact factor: 6.150

5.  Alzheimer's disease drug development pipeline: 2020.

Authors:  Jeffrey Cummings; Garam Lee; Aaron Ritter; Marwan Sabbagh; Kate Zhong
Journal:  Alzheimers Dement (N Y)       Date:  2020-07-16

6.  Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis.

Authors:  Timo Sarajärvi; Annakaisa Haapasalo; Jayashree Viswanathan; Petra Mäkinen; Marjo Laitinen; Hilkka Soininen; Mikko Hiltunen
Journal:  J Biol Chem       Date:  2009-10-08       Impact factor: 5.157

7.  The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau.

Authors:  Lin-Lin Shen; Noralyn B Mañucat-Tan; Shi-Hao Gao; Wei-Wei Li; Fan Zeng; Chi Zhu; Jun Wang; Xian-Le Bu; Yu-Hui Liu; Chang-Yue Gao; Zhi-Qiang Xu; Larisa Bobrovskaya; Peng Lei; Jin-Tai Yu; Weihong Song; Hua-Dong Zhou; Xiu-Qing Yao; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Mol Psychiatry       Date:  2018-06-04       Impact factor: 15.992

Review 8.  Alzheimer's disease.

Authors:  Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier
Journal:  Lancet       Date:  2021-03-02       Impact factor: 79.321

Review 9.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

10.  Characterization of an alternative BAK-binding site for BH3 peptides.

Authors:  Kaiqin Ye; Wei X Meng; Hongbin Sun; Bo Wu; Meng Chen; Yuan-Ping Pang; Jia Gao; Hongzhi Wang; Junfeng Wang; Scott H Kaufmann; Haiming Dai
Journal:  Nat Commun       Date:  2020-07-03       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.